Login to Your Account



AS ALNYLAM PHASE III MOTORS ON

Triple A: Arbutus on road to further deals with LNP after $82M Alexion tie-up

By Randy Osborne
Staff Writer

Monday, March 20, 2017

In what CEO Mark Murray told BioWorld Today may signal "the first of a number of deals," hepatitis B virus (HBV)-focused Arbutus Biopharma Corp. is bringing aboard $7.5 million up front and as much as $75 million in development, regulatory and commercial milestone payments from Alexion Pharmaceuticals Inc. for the lipid nanoparticle (LNP) technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription